LCB1   Click here for help

GtoPdb Ligand ID: 11236

Comment: A synthetic peptide that binds potently to the ACE2 binding domain of the SARS-CoV-2 spike protein, and blocks entry of SARS-CoV-2 in vitro. The peptide sequence was obtained from supplementary table S2 in the original article [1]. The chemical SMILES was generated using the HELM editor. Note that the peptide in the PDB crystal complex with SARS-CoV-2 spike is shorter by one amino acid (missing the Arg at the COOH terminal) than the sequence we show here - see 7JZL .
Click here for help
2D Structure
Click here for help
Click here for structure editor
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES NCCCC[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)O)CCCNC(=N)N)CCC(=O)O)C(C)C)CCC(=O)O)CCC(=O)O)CC(C)C)CC(C)C)CCCNC(=N)N)CCC(=O)O)C)CCC(=O)O)CCC(=O)O)CC(C)C)CC(C)C)CCCNC(=N)N)CCC(=O)O)CC(=O)O)CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]([C@H](CC)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]([C@H](CC)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]([C@H](CC)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]([C@H](CC)C)NC(=O)[C@H](Cc1c[nH]c2c1cccc2)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)N)CCCCN)CCC(=O)O)CC(C)C)CCC(=O)N)CCCCN)Cc1ccc(cc1)O)CCC(=O)O)CCSC)CCCNC(=N)N)CC(C)C)CC(C)C)CC(=O)O)CCC(=O)O)CC(C)C)C)CCC(=O)O)C)CO)CCSC)CCCNC(=N)N)CO)CC(=O)O)CC(C)C)Cc1ccc(cc1)O)CCC(=O)O)Cc1ccccc1)CCSC
Isomeric SMILES NCCCC[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)O)CCCNC(=N)N)CCC(=O)O)C(C)C)CCC(=O)O)CCC(=O)O)CC(C)C)CC(C)C)CCCNC(=N)N)CCC(=O)O)C)CCC(=O)O)CCC(=O)O)CC(C)C)CC(C)C)CCCNC(=N)N)CCC(=O)O)CC(=O)O)CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]([C@H](CC)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]([C@H](CC)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]([C@H](CC)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]([C@H](CC)C)NC(=O)[C@H](Cc1c[nH]c2c1cccc2)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)N)CCCCN)CCC(=O)O)CC(C)C)CCC(=O)N)CCCCN)Cc1ccc(cc1)O)CCC(=O)O)CCSC)CCCNC(=N)N)CC(C)C)CC(C)C)CC(=O)O)CCC(=O)O)CC(C)C)C)CCC(=O)O)C)CO)CCSC)CCCNC(=N)N)CO)CC(=O)O)CC(C)C)Cc1ccc(cc1)O)CCC(=O)O)Cc1ccccc1)CCSC
InChI Key NDMHMGNPFJKEIS-HNVXLNGZSA-N
Bioactivity Comments
LBD1 neutralises SARS-CoV-2 infection of Vero E6 cells with an IC50 of 23.54 pM.
Selectivity at other protein targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
CoV Spike glycoprotein SARS-CoV-2 None Binding >9.0 pKd - 1
pKd >9.0 (Kd <1x10-9 M) [1]